A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 13, 2009

Primary Completion Date

November 20, 2009

Study Completion Date

November 20, 2009

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

GSK1362885

100mg in the AM, 100mg in the PM, 50mg BID

DRUG

GSK1362885

100mg in the PM, 100mg in the AM, 50mg BID

Trial Locations (2)

GSK Investigational Site, Phoenix

GSK Investigational Site, Saint Paul